

## Alchemia

ACL AU / ACL.AX

Market Cap  
**US\$169.3m**  
 A\$181.7m

Avg Daily Turnover  
**US\$0.18m**  
 A\$0.19m

Free Float  
**80.0%**  
 324.0 m shares

Current **A\$0.56**  
 Target **A\$0.88**  
 Prev. Target **A\$0.88**  
 Up/Downside **57.4%**

## COMPANY NOTE

### STOCK RATING

ADD

HOLD

REDUCE

### Morgans Analyst(s)

#### Scott POWER

T (61) 7 3334 4884

E scott.power@morgans.com.au

# Moment of truth approaches

*ACL plans to report top line results for its pivotal Phase III trial in metastatic colorectal cancer this quarter. We are confident of a successful read out and we have run some sensitivities on the impact on our price target. In this note we review a number of the existing treatments and other compounds in development and reflect on the clinical trial so far.*

We have made no changes to our forecasts ahead of the Phase III read out. As a result our price target and DCF valuation currently sit at A\$0.88. Our model is most sensitive to changes in the probability of success (currently at 70%), with a 5% change increasing /decreasing our valuation by A\$0.04/(A\$0.04). If the Phase III trial is successful we would move our probability calculation to 90% and subsequently the price target to A\$1.04. ACL is in a solid cash position with A\$11.1m in cash at 30 June 2014.


## Phase III read out this quarter

ACL is due to report in September top line data for its 415 patients phase III clinical trial in metastatic colorectal cancer (mCRC). The primary endpoint of the trial is at least 6 weeks improvement in median

progression free survival (PFS). If the trial results are positive (as we expect) then the time lines to approval would include a regulatory submission in 1HCY15, additional data from the trial, as well as data from the CHIME trial (see report for more detail) with a product launch expected in 1HFY16. We have assumed a licensing deal is entered into in FY15. Depending on the timing of a licensing transaction, we do not rule out the need for additional capital.

## What you should do

Clearly this is a binary event for ACL, with the risk being a poor clinical trial outcome and the share price falling below our fondaparinux valuation of A\$0.31ps. If a client's risk appetite is appropriate, ACL is solid risk/reward play.



## Financial Summary


	Jun-12A	Jun-13A	Jun-14F	Jun-15F	Jun-16F
Revenue (A\$m)	0.34	24.08	13.62	57.42	42.68
Operating EBITDA (A\$m)	-14.14	-3.67	-3.12	48.22	33.21
Net Profit (A\$m)	-15.08	-4.79	-3.74	47.36	23.84
Normalised EPS (A\$)	-0.05	-0.01	-0.01	0.15	0.07
Normalised EPS Growth	(21.6%)	(73.1%)	(22.0%)	NA	(49.7%)
FD Normalised P/E (x)	NA	NA	NA	3.83	7.61
DPS (A\$)	-	-	-	-	-
Dividend Yield	0%	0%	0%	0%	0%
EV/EBITDA (x)	NA	NA	NA	2.72	3.06
P/FCFE (x)	NA	NA	NA	NA	NA
Net Gearing	(57.8%)	(40.1%)	(52.8%)	(66.1%)	(79.9%)
P/BV (x)	6.35	5.60	6.33	2.39	1.82
ROE	(70.0%)	(16.9%)	(12.2%)	90.5%	27.1%
% Change In Normalised EPS Estimates			0%	0%	0%
Normalised EPS/consensus EPS (x)			1.05	1.06	0.43

SOURCE: MORGANS, COMPANY REPORTS


### Share price info

Share px perf. (%)	1M	3M	12M
Relative	-10.4	4.8	45.8
Absolute	-9.7	5.7	53.4
Major shareholders	% held		
Alan Gray	19.9		

### P/BV vs ROE



### 12-mth Fwd FD Normalised P/E vs FD Normalised EPS Growth



### Profit & Loss

(A\$m)	Jun-12A	Jun-13A	Jun-14F	Jun-15F	Jun-16F
<b>Total Net Revenues</b>	<b>0.34</b>	<b>24.08</b>	<b>13.62</b>	<b>57.42</b>	<b>42.68</b>
<b>Gross Profit</b>	<b>0.34</b>	<b>24.08</b>	<b>13.62</b>	<b>57.42</b>	<b>42.68</b>
<b>Operating EBITDA</b>	<b>-14.14</b>	<b>-3.67</b>	<b>-3.12</b>	<b>48.22</b>	<b>33.21</b>
Depreciation And Amortisation	-1.73	-1.60	-1.44	-1.45	-1.45
<b>Operating EBIT</b>	<b>-15.87</b>	<b>-5.28</b>	<b>-4.55</b>	<b>46.76</b>	<b>31.75</b>
Financial Income/(Expense)	0.39	0.22	0.82	0.61	2.01
Pretax Income/(Loss) from Assoc.	0.00	0.00	0.00	0.00	0.00
Non-Operating Income/(Expense)	0.00	0.00	0.00	0.00	0.00
<b>Profit Before Tax (pre-EI)</b>	<b>-15.48</b>	<b>-5.06</b>	<b>-3.74</b>	<b>47.37</b>	<b>33.76</b>
Exceptional Items					
<b>Pre-tax Profit</b>	<b>-15.48</b>	<b>-5.06</b>	<b>-3.74</b>	<b>47.37</b>	<b>33.76</b>
Taxation	0.40	0.27	0.00	-0.01	-9.93
Exceptional Income - post-tax	0.00	0.00	0.00	0.00	0.00
<b>Profit After Tax</b>	<b>-15.08</b>	<b>-4.79</b>	<b>-3.74</b>	<b>47.36</b>	<b>23.84</b>
Minority Interests	0.00	0.00	0.00	0.00	0.00
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Preference Dividends (Australia)					
<b>Net Profit</b>	<b>-15.08</b>	<b>-4.79</b>	<b>-3.74</b>	<b>47.36</b>	<b>23.84</b>
Normalised Net Profit	-15.08	-4.79	-3.74	47.36	23.84
<b>Fully Diluted Normalised Profit</b>	<b>-15.08</b>	<b>-4.79</b>	<b>-3.74</b>	<b>47.36</b>	<b>23.84</b>

### Cash Flow

(A\$m)	Jun-12A	Jun-13A	Jun-14F	Jun-15F	Jun-16F
EBITDA	-14.14	-3.67	-3.12	48.22	33.21
Cash Flow from Invt. & Assoc.	0.00	0.00	0.00	0.00	0.00
Change In Working Capital	1.55	-12.65	4.73	-13.61	4.39
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	0.00	0.00	0.00	0.00	0.00
Net Interest (Paid)/Received	0.39	0.22	0.82	0.61	2.01
Tax Paid	0.40	0.27	0.00	-0.01	-9.93
<b>Cashflow From Operations</b>	<b>-11.80</b>	<b>-15.84</b>	<b>2.43</b>	<b>35.20</b>	<b>29.68</b>
Capex	-0.07	-0.09	-0.28	-0.11	-0.13
Disposals Of FAs/subsidiaries	0.00	0.00	0.00	0.00	0.00
Acq. Of Subsidiaries/investments	0.00	0.00	0.00	0.00	0.00
Other Investing Cashflow	0.37	-6.23	0.00	0.00	0.00
<b>Cash Flow From Investing</b>	<b>0.30</b>	<b>-6.33</b>	<b>-0.28</b>	<b>-0.11</b>	<b>-0.13</b>
Debt Raised/(repaid)	-8.60	9.68	-2.15	-35.09	-29.55
Proceeds From Issue Of Shares	20.09	12.48	0.00	0.00	0.00
Shares Repurchased					
Dividends Paid	0.00	0.00	0.00	0.00	0.00
Preferred Dividends	0.00	0.00	0.00	0.00	0.00
Other Financing Cashflow	0.00	0.00	0.00	0.00	0.00
<b>Cash Flow From Financing</b>	<b>11.49</b>	<b>22.16</b>	<b>-2.15</b>	<b>-35.09</b>	<b>-29.55</b>
Total Cash Generated	0.00	0.00	0.00	0.00	0.00
<b>Free Cashflow To Equity</b>	<b>-20.09</b>	<b>-12.48</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>Free Cashflow To Firm</b>	<b>-11.88</b>	<b>-22.38</b>	<b>1.34</b>	<b>34.49</b>	<b>27.54</b>

BY THE NUMBERS

## BY THE NUMBERS

### Balance Sheet

(A\$m)	Jun-12A	Jun-13A	Jun-14F	Jun-15F	Jun-16F
Total Cash And Equivalents	14.02	12.98	15.13	50.22	79.78
Total Debtors	0.08	12.38	3.36	14.16	10.52
Inventories	0.00	0.00	0.68	2.87	2.13
Total Other Current Assets	1.57	0.68	0.68	0.68	0.68
<b>Total Current Assets</b>	<b>15.67</b>	<b>26.04</b>	<b>19.85</b>	<b>67.93</b>	<b>93.11</b>
Fixed Assets	0.39	0.43	0.59	0.57	0.58
Total Investments	0.00	0.00	0.00	0.00	0.00
Intangible Assets	16.06	14.73	13.41	12.08	10.76
Total Other Non-Current Assets	0.25	0.30	0.30	0.30	0.30
<b>Total Non-current Assets</b>	<b>16.70</b>	<b>15.45</b>	<b>14.29</b>	<b>12.95</b>	<b>11.63</b>
Short-term Debt	0.00	0.00	0.00	0.00	0.00
Current Portion of Long-Term Debt					
Total Creditors	3.32	4.99	1.38	0.76	0.78
Other Current Liabilities	1.69	0.88	0.89	0.89	0.89
<b>Total Current Liabilities</b>	<b>5.01</b>	<b>5.87</b>	<b>2.26</b>	<b>1.64</b>	<b>1.66</b>
Total Long-term Debt	0.00	0.00	0.00	0.00	0.00
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00
<b>Total Non-current Liabilities</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
Total Provisions	3.10	3.24	3.24	3.24	3.24
<b>Total Liabilities</b>	<b>8.11</b>	<b>9.11</b>	<b>5.50</b>	<b>4.88</b>	<b>4.90</b>
Shareholders' Equity	24.27	32.38	28.64	76.00	99.84
Minority Interests	0.00	0.00	0.00	0.00	0.00
<b>Total Equity</b>	<b>24.27</b>	<b>32.38</b>	<b>28.64</b>	<b>76.00</b>	<b>99.84</b>

### Key Ratios

	Jun-12A	Jun-13A	Jun-14F	Jun-15F	Jun-16F
Revenue Growth	(59%)	6962%	(43%)	322%	(26%)
Operating EBITDA Growth	12.2%	(74.0%)	(15.2%)	NA	(31.1%)
Operating EBITDA Margin	(4145%)	(15%)	(23%)	84%	78%
Net Cash Per Share (A\$)	0.05	0.04	0.05	0.16	0.25
BVPS (A\$)	0.09	0.10	0.09	0.23	0.31
Gross Interest Cover	-100,442	-33,407	-28,836	296,028	201,018
Effective Tax Rate	0.0%	0.0%	0.0%	0.0%	29.4%
Net Dividend Payout Ratio	NA	NA	NA	NA	NA
Accounts Receivables Days	42.4	94.4	210.9	55.7	105.8
Inventory Days	N/A	N/A	N/A	N/A	N/A
Accounts Payables Days	N/A	N/A	N/A	N/A	N/A
ROIC (%)	(120%)	(40%)	(20%)	279%	78%
ROCE (%)	(71.8%)	(17.9%)	(12.2%)	90.5%	38.4%

SOURCE: MORGANS COMPANY REPORTS

# Recap on the program

## 1. Colorectal cancer treatment overview

### 1.1 Fourth most common cancer ▶

Colorectal cancer (CRC) is a cancer that develops in the colon or rectum. Current prognosis for the disease is poor, with a five-year survival rate of less than 60%, dropping as low as 5%, depending on detection and type of cancer. Globally more than one million cases occur each year, resulting in over 700,000 deaths. CRC is the fourth most common cause of cancer death. The rate of CRC diagnosis has increased, especially in Asia, attributed to uptake of a “Western lifestyle”: poor diet and reduced exercise at old age.

### 1.2 Treatment options and approved drugs▶

The main categories of treatment for cancers are: surgery (remove it), chemotherapy (poison it), radiotherapy (irradiate it) or biologic therapies (interrupt it). In the case of CRC if the cancer progresses to metastatic colorectal cancer the clinician will usually choose a chemotherapy combination. The FDA has approved nine non-surgery treatments for CRC, which can be split in two categories: chemotherapies (Figure 1) and targeted therapies (Figure 2). Fluorouracil combined with Irinotecan (known as FOLFIRI) is used as first line treatment in Europe and second line treatment in Australia and US.

**Figure 1: Chemotherapies (in order of FDA approval)**

Fluorouracil – blocks DNA replication
Irinotecan (Pfizer) – a topoisomerase-1 inhibitor
Oxaliplatin (Sanofi) – platinum-based therapy blocking DNA synthesis
Capecitabine (Roche) – a prodrug metabolised to fluorouracil

SOURCES: MORGANS, COMPANY REPORTS

**Figure 2: Targeted therapies**

Avastin - Bevacizumab (Roche) – humanized VEGF-A inhibitor
Vectobix - Panitumab (Amgen) – fully humanized EGFR inhibitor
Erbix - Cetuximab (Eli Lilly) – partially humanized EGFR inhibitor
Zaltrap - Aflibercept (Regeneron) – Recombinant fusion protein for VEGF inhibition
Stivarga - Regorafenib (Bayer) – multi-kinase inhibitor targeting angiogenic, stromal and oncogenic RTKs

SOURCES: MORGANS, COMPANY REPORTS

### 1.3 New treatments under development

ACL has developed a treatment for mCRC by combining irinotecan with hyaluronic acid, which increases the amount of irinotecan that is targeted to the tumour, allowing for a greater dose of the irinotecan with reduced toxicity. Excluding ACL's product, there are five notable novel treatments in development for CRC, refer Figure 3. ACL's clinical data to date supports further clinical development, refer Figure 4. Results from the phase II trial were strong, with a 12 week extension in median progression free survival (PFS) and no change in safety or dosing schedule compared to irinotecan alone.

**Figure 3: Novel treatments**


Novel treatments in development for CRC	Phase of development
MGN1703 (Mologen AG) – immunotherapy designed as a TLR9 agonist	2
Imprime PGG (Biothera) – immunotherapy binding CR3 to target tumour cells	3
Xilonix (XBioTech) – humanized IL-1 $\alpha$ inhibitor	3
BAY 43-9006 (Bayer) – multi-kinase inhibitor, including VEGFR, PDGFR and Raf kinases	2
TAS 102 (Taiho Oncology) – combination of a DNA synthesis inhibitor (FTD) and a compound to prevent FTD degradation,	phase 3 (primary endpoint met 12/5/14)

SOURCES: MORGANS, COMPANY REPORTS

**Figure 4: Phase II Data supports further clinical development**

Gibbs et al. *Cancer Chemother. Pharmacol.* Mar 2010

*HA-Irinotecan provided 12 week extension in median PFS with no change in safety, dosing schedule or PK compared with irinotecan alone*



SOURCES: Prof Gibbs et al. *Cancer Chemother, Pharmacol*, March 2010


### 1.4 ACL's Phase III trial about to read out

ACL's Phase III enrolment was completed in February 2013, with a total of 415 patients across 76 centres in Australia, UK, and Europe. Top-line data is expected in September 2014. The trial is comparing the standard CRC chemotherapy treatment FOLFIRI (fluorouracil combined with irinotecan) to FOLF(HA)iri, which uses HA-irinotecan instead, refer Figure 5. The primary endpoint of the study is PFS of six weeks or more.

**Figure 5: Phase III trial design**

ClinicalTrials.gov Identifier: NCT01290783


*Trial completed enrolment of 415 patients in February 2013  
Top-line data (primary endpoint) expected in September 2014*



\* 76 centers in Australia, UK, Eastern EU and Western EU

SOURCES: MORGANS, COMPANY REPORTS

## 1.5 Outline of timeline to approval



## 1.6 Clinical considerations

Assuming success in phase III trial and regulatory filing, HA-irinotecan would be positioned as a strong choice compared to standard irinotecan as a first, second or third line treatment for CRC given its benefits of reduced toxicity and improved PFS. However, success in uptake of the treatment would also depend on drug cost as well as the market and marketing. An important consideration is whether HA-irinotecan, a chemotherapy, will be used by clinicians in combination with targeted therapies. To address this, a secondary study (CHIME trial), in phase II, is examining the efficacy of FOLF(HA)iri combined with cetuximab, a common targeted therapy for CRC. Management has undertaken clinician surveys and believe that a 2 month difference in PFS would change practice by 50% uptake.

## 1.7 Other programs underway

ACL has a number of other clinical programs underway including two investigator sponsored trials. A Phase II small cell lung cancer trial of 40 patients and a Phase II trial using HA-Irinotecan in the FOLFIRI regimen administered with Erbitux (known as the CHIME trial).

## 2. VALUATION & SENSITIVITIES

### 2.1 If successful valuation upgrade ►

We have made no changes to our forecasts ahead of the Phase III read out. As a result our price target and DCF valuation currently sit at A\$0.88. Our model is most sensitive to changes in the probability of success (currently at 70%), with a 5% change increasing /decreasing our valuation by A\$0.04/(A\$0.04). If the Phase III trial is successful we would move our probability calculation to 90% and subsequently the price target to A\$1.04.

Cash position is sound at A\$11.1m as at 30 June 2014.

## 3. Risks

Clearly this is a binary event for ACL, with the risk being a poor clinical trial outcome and the share price falling below our fondaparinux valuation of A\$0.31ps. If a client's risk appetite is appropriate, ACL is solid risk/reward play.

## QUEENSLAND

BRISBANE	(07) 3334 4888
BUNDABERG	(07) 4153 1050
CAIRNS	(07) 4222 0555
CALOUNDRA	(07) 5491 5422
CHERMSIDE	(07) 3350 9000
EDWARD STREET	(07) 3121 5677
EMERALD	(07) 4988 2777
GLADSTONE	(07) 4972 8000
GOLD COAST	(07) 5581 5777
IPSWICH/SPRINGFIELD	(07) 3202 3995
MACKAY	(07) 4957 3033
MILTON	(07) 3114 8600
MT GRAVATT/CAPALABA	(07) 3245 5466
NOOSA	(07) 5449 9511
REDCLIFFE	(07) 3897 3999
ROCKHAMPTON	(07) 4922 5855
SPRING HILL	(07) 3833 9333
SUNSHINE COAST	(07) 5479 2757
TOOWOOMBA	(07) 4639 1277
TOWNSVILLE	(07) 4725 5787
YEPPON	(07) 4939 3021

## NEW SOUTH WALES

SYDNEY	(02) 8215 5055
ARMIDALE	(02) 6770 3300
BALLINA	(02) 6686 4144
BALMAIN	(02) 8755 3333
CHATSWOOD	(02) 8116 1700
COFFS HARBOUR	(02) 6651 5700
GOSFORD	(02) 4325 0884
HURSTVILLE	(02) 9570 5755
MERIMBULA	(02) 6495 2869
NEUTRAL BAY	(02) 8969 7500
NEWCASTLE	(02) 4926 4044
NEWPORT	(02) 9998 4200
ORANGE	(02) 6361 9166

PORT MACQUARIE	(02) 6583 1735
SCONE	(02) 6544 3144
SYDNEY – LEVEL 9	(02) 8215 5000
SYDNEY – LEVEL 33	(02) 8216 5111
SYDNEY – HUNTER STREET	(02) 9125 1788

SYDNEY – REYNOLDS EQUITIES	(02) 9615 4500
WOLLONGONG	(02) 9373 4452
	(02) 4227 3022

<b>ACT</b>	
CANBERRA	(02) 6232 4999

<b>VICTORIA</b>	
MELBOURNE	(03) 9947 4111
BRIGHTON	(03) 9519 3555
CAMBERWELL	(03) 9813 2945
CARLTON	(03) 9066 3200
FARRER HOUSE	(03) 8644 5488
GEELONG	(03) 5222 5128
RICHMOND	(03) 9916 4000
SOUTH YARRA	(03) 9098 8511
TRARALGON	(03) 5176 6055
WARRNAMBOOL	(03) 5559 1500

<b>WESTERN AUSTRALIA</b>	
PERTH	(08) 6462 1999

<b>SOUTH AUSTRALIA</b>	
ADELAIDE	(08) 8464 5000
NORWOOD	(08) 8461 2800

<b>NORTHERN TERRITORY</b>	
DARWIN	(08) 8981 9555

<b>TASMANIA</b>	
HOBART	(03) 6236 9000

## DISCLAIMER

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("Morgans") do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so. Those acting upon such information without advice do so entirely at their own risk.

This report was prepared as private communication to clients of Morgans and is not intended for public circulation, publication or for use by any third party. The contents of this report may not be reproduced in whole or in part without the prior written consent of Morgans. While this report is based on information from sources which Morgans believes are reliable, its accuracy and completeness cannot be guaranteed. Any opinions expressed reflect Morgans judgement at this date and are subject to change. Morgans is under no obligation to provide revised assessments in the event of changed circumstances. This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever.

Although CIMB Securities (Australia) Ltd (ABN 84 002 768 701), its related bodies corporate, directors and officers, employees, authorised representatives and agents ("CIMB Securities Australia") may have been involved in the preparation of certain content for this Research Report, this Research Report constitutes general advice provided by Morgans to the recipient of this report under its Australian financial services licence and Morgans is solely responsible for the content of this report. CIMB Securities Australia do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within.

## DISCLOSURE OF INTEREST

Morgans and CIMB Securities Australia may from time to time hold an interest in any security referred to in this report and may, as principal or agent, sell such interests. Morgans or CIMB Securities Australia may previously have acted as manager or co-manager of a public offering of any such securities. Morgans' affiliates or CIMB Securities Australia affiliates may provide or have provided banking services or corporate finance to the companies referred to in the report. The knowledge of affiliates concerning such services may not be reflected in this report. Each of Morgans and CIMB Securities Australia advises that it may earn brokerage, commissions, fees or other benefits and advantages, direct or indirect, in connection with the making of a recommendation or a dealing by a client in these securities. Some or all of Morgans' Authorised Representatives may be remunerated wholly or partly by way of commission.

## RECOMMENDATION STRUCTURE

For a full explanation of the recommendation structure, refer to our website at [https://www.morgans.com.au/research\\_disclaimer](https://www.morgans.com.au/research_disclaimer).

**If you no longer wish to receive Morgans' publications please advise your local Morgans office or write to Morgans, Reply Paid 202, Brisbane QLD 4001 and include your account details.**